Safety and clinical performance of a drug eluting absorbable metal scaffold in the treatment of subjects with de novo lesions in native coronary arteries: Pooled 12-month outcomes of BIOSOLVE-II and BIOSOLVE-III.
Michael HaudeHüseyin InceStephan KischeAlexandre AbizaidRalph TölgPedro Alves Lemos NetoNicolas M Van MieghemStefan VerheyeClemens von BirgelenEvald Høj ChristiansenEmanuele BarbatoHector M Garcia-GarciaRon Waksmannull nullPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2018)
The pooled outcomes of BIOSOLVE-II and BIOSOLVE-III provide further evidence on the safety and performance of a novel drug-eluting absorbable metal scaffold with constant clinical and angiographic performance parameters at 12 months and no definite or probable scaffold thrombosis.